Vertex Pharmaceuticals

Health Care Biotechnology Boston, Massachusetts Last filing Feb 13, 2026 · FY2025

                    Revenue
                    FY2025
                
$12.0B
                    3y CAGR +10.4%
                    
                    P75
                    
                    n/a
                    
                    Net income
                    FY2025
                
$4.0B
                    Net margin +32.9%
                    
                    P100
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$25.6B
                    ROA +15.4%
                    
                    P90
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$3.6B
                    FCF margin +26.6%
                    
                    P92
                    
                    n/a

19 yrs · FY2003–FY2025 4 gaps (2007–2004) 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s total assets.

Balance Sheet

Assets, liabilities, and equity

27 accounts · 1 year

Total assets $25.6B

Total liabilities $7.0B

Shareholders equity $18.7B

Account	2025	Trend
Assets
Cash and Cash Equivalents	19.8%
Short Term Investments	0.1%
Accounts Receivable	8.0%
Inventory	6.6%
Prepaid Expenses	3.3%
Total Current Assets	43.7%
Property,Plant and Equipment	5.9%
Operating Lease Assets	6.1%
Goodwill	4.2%
Intangible Assets	1.7%
Deferred Tax Assets	11.3%
Other Noncurrent Assets	4.8%
Total Assets	100.0%
Liabilities
Accounts Payable	1.8%
Accrued Liabilities	11.6%
Other Current Liabilities	1.7%
Total Current Liabilities	15.1%
Operating Lease Liabilities Noncurrent	7.2%
Other Noncurrent Liabilities	5.0%
Total Liabilities	27.2%
Equity
Preferred Stock	0.0%
Common Stock	0.0%
Additional Paid In Capital	20.0%
Retained Earnings	52.9%
Accumulated Other Comprehensive Income	-0.1%
Total Stockholders Equity	72.8%
Total Liabilitiesand Equity	100.0%

Income Statement

Revenue, expense, and profitability

18 accounts · 1 year

Revenue $12.0B

Operating income $4.2B

Net income $4.0B

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	46.8%
Expenses Cost of Revenue	6.4%
Expenses Research and Development	15.2%
Expenses Selling,General and Administrative	6.8%
Expenses Depreciation and Amortization	0.8%
Expenses Share Based Compensation	2.7%
Expenses Operating Expenses	30.5%
Other Income Expense Operating Income	16.3%
Other Income Expense Interest Expense	0.1%
Other Income Expense Other Income/expense	-0.0%
Other Income Expense Income Before Tax	18.1%
Income Tax Income Tax Expense	2.7%
net Income net Income	15.4%
net Income Comprehensive Income	14.9%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Basic	1.0%
Earnings Per Share Weighted Average Shares Diluted	1.0%

Cash Flow Statement

Operating, investing, and financing flows

21 accounts · 1 year

Operating cash flow $3.6B

Investing cash flow $-945.4M

Financing cash flow $-2.3B

Account	2025	Trend
CashFlow
Operating Activities net Income	15.4%
Operating Activities Depreciation and Amortization	0.8%
Operating Activities Stock Based Compensation	2.7%
Operating Activities Deferred Income Taxes	-2.0%
Operating Activities Changes In Operating Assets and Liabilities	5.1%
Operating Activities Other Non Cash Items	0.6%
Operating Activities net Cash From Operating Activities	14.2%
Investing Activities Capital Expenditures	1.7%
Investing Activities Purchases of Investments	24.9%
Investing Activities Proceeds From Sale of Investments	23.0%
Investing Activities Other Investing Activities	0.1%
Investing Activities net Cash From Investing Activities	-3.7%
Financing Activities Repurchase of Common Stock	7.9%
Financing Activities Proceeds From Stock Issuance	0.2%
Financing Activities Tax Withholding On Stock Based Compensation	1.4%
Financing Activities Other Financing Activities	0.0%
Financing Activities net Cash From Financing Activities	-8.8%
Cash Reconciliation Effect of Exchange Rate On Cash	0.4%
Cash Reconciliation net Change In Cash	2.0%
Cash Reconciliation Cash At Beginning of Period	19.8%
Cash Reconciliation Cash At End of Period	19.8%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+86.2%
Operating margin	+34.8%
Net margin	+32.9%
FCF margin	+26.6%
Growth
Revenue CAGR (3y)	+10.4%
Returns
ROE	+21.2%
ROA	+15.4%
ROIC	—
Liquidity
Current ratio	2.90x
Quick ratio	1.85x
Leverage
D/E	0.37x
Interest coverage	313.78x
Efficiency
Asset turnover	0.47x
Cash conversion cycle	+333d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Vertex Pharmaceuticals

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history